Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA), which has announced a transition to the name LeonaBio, Inc. with a new ticker "LONA," regularly issues news updates as a clinical-stage biopharmaceutical company headquartered in the Seattle, Washington area. Its press releases focus on the development of novel small molecule therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
News for ATHA commonly covers progress in the company’s lead programs, lasofoxifene and ATH-1105. Updates include clinical trial milestones such as completion of a first-in-human Phase 1 trial of ATH-1105 in healthy volunteers, presentations of safety, tolerability and pharmacokinetic data, and enrollment status for the Phase 3 ELAINE-3 trial of lasofoxifene in ER+, HER2-negative, ESR1-mutated metastatic breast cancer. The company also reports on preclinical findings for ATH-1105 in ALS models and scientific presentations at major neurology and ALS-focused conferences.
Investors following ATHA news will also see corporate and regulatory developments, including announcements about a 10-for-1 reverse stock split aimed at maintaining Nasdaq listing requirements, notices of regained compliance with the minimum bid price rule, and details of private placement financings intended to support clinical and regulatory milestones. Additional releases describe Athira’s strategic alternatives review and its licensing agreements with Sermonix Pharmaceuticals and Ligand Pharmaceuticals for lasofoxifene.
This news feed provides a centralized view of Athira/LeonaBio’s clinical, scientific and corporate disclosures, allowing readers to track how its oncology and neurology pipelines evolve over time and how financing and licensing arrangements relate to ongoing and planned trials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Athira Pharma, Inc. (NASDAQ: ATHA) revealed significant findings from its Phase 2 ACT-AD trial and new preclinical data during the AAN 2023 Annual Meeting. A post hoc analysis showed that patients treated with fosgonimeton exhibited a notable improvement in Mini-Mental State Examination (MMSE) scores (+1.6 pts, p=0.0350) and a decrease in neurodegeneration biomarkers. Additionally, preclinical data on ATH-1105 indicated prolonged survival and improved motor function in ALS mouse models. Athira continues to advance its exploration of the HGF/MET neurotrophic system as a potential treatment for neurodegenerative diseases, positioning ATHA for future clinical evaluation.
Athira Pharma, a biopharmaceutical company, announced upcoming presentations at the American Academy of Neurology (AAN) Annual Meeting, scheduled for April 22-27, 2023, in Boston. The presentations will feature new clinical data from the completed Phase 2 ACT-AD trial of fosgonimeton for Alzheimer's disease, showcasing improvements in cognitive measures and plasma biomarkers. Additionally, preclinical research will support the therapeutic potential of fosgonimeton and ATH-1105 in neurodegenerative conditions, including ALS. The oral presentations will be led by Dr. Kevin Church and Dr. Hans J. Moebius on April 24 and 25, respectively. A poster presentation on ATH-1105's impact on motor function in an ALS model will occur on April 25. All presentations will be accessible on Athira's website post-event.
Athira Pharma (NASDAQ: ATHA) recently showcased preclinical data at the AD/PD 2023 conference, indicating that fosgonimeton may provide significant neuroprotective, neurotrophic, and anti-inflammatory benefits. Highlights include protection against neurite degeneration and cell death in neuronal cultures, reduced hyperphosphorylated tau levels, and decreased α-synuclein aggregation. The data suggests fosgonimeton could play a role in addressing Alzheimer’s and Parkinson’s diseases. Athira focuses on developing small molecules to restore neuronal health and progress its pipeline targeting the HGF/MET neurotrophic system.